Adicet Bio (ACET) Cash & Equivalents (2017 - 2026)

Adicet Bio's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $36.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 28.83% year-over-year to $36.2 million; the TTM figure through Mar 2026 stood at $36.2 million (up 28.83% YoY), while the FY2025 annual figure was $38.9 million, down 31.11% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $36.2 million, down from $38.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $282.7 million in Q3 2022, with the low at $28.1 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $159.7 million (2023), against an average of $151.3 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents surged 47.06% in 2022, then slumped 84.5% in 2025.
• Adicet Bio's Cash & Equivalents stood at $257.7 million in 2022, then plunged by 38.01% to $159.7 million in 2023, then sank by 64.63% to $56.5 million in 2024, then slumped by 31.11% to $38.9 million in 2025, then fell by 6.87% to $36.2 million in 2026.
• Business Quant data shows ACET's Cash & Equivalents at $36.2 million in Q1 2026, $38.9 million in Q4 2025, and $29.1 million in Q3 2025.